140 related articles for article (PubMed ID: 37072259)
1. Identification of novel class inhibitors of NSD3 methyltransferase showing a unique, bivalent binding mode in the SET domain.
Kim S; Hwang I; Kim SH; Chung HW; Ji MJ; Moon S; Park HM; Kong G; Hur W
Chem Biol Drug Des; 2023 Sep; 102(3):500-513. PubMed ID: 37072259
[TBL] [Abstract][Full Text] [Related]
2. Elevated NSD3 histone methylation activity drives squamous cell lung cancer.
Yuan G; Flores NM; Hausmann S; Lofgren SM; Kharchenko V; Angulo-Ibanez M; Sengupta D; Lu X; Czaban I; Azhibek D; Vicent S; Fischle W; Jaremko M; Fang B; Wistuba II; Chua KF; Roth JA; Minna JD; Shao NY; Jaremko Ł; Mazur PK; Gozani O
Nature; 2021 Feb; 590(7846):504-508. PubMed ID: 33536620
[TBL] [Abstract][Full Text] [Related]
3. NSD3, a member of nuclear receptor-binding SET domain family, is a potential prognostic biomarker for pancreatic cancer.
Xiong Q; Zhou Y; Zhang S; Zhang Y; Xu Y; Yang Y; Zhou C; Zeng Z; Han J; Zhu Q
Cancer Med; 2023 May; 12(9):10961-10978. PubMed ID: 37062069
[TBL] [Abstract][Full Text] [Related]
4. NSD3-Induced Methylation of H3K36 Activates NOTCH Signaling to Drive Breast Tumor Initiation and Metastatic Progression.
Jeong GY; Park MK; Choi HJ; An HW; Park YU; Choi HJ; Park J; Kim HY; Son T; Lee H; Min KW; Oh YH; Lee JY; Kong G
Cancer Res; 2021 Jan; 81(1):77-90. PubMed ID: 32967925
[TBL] [Abstract][Full Text] [Related]
5. Backbone resonance assignments for the SET domain of human methyltransferase NSD3 in complex with its cofactor.
Li Y; Ng HQ; Ngo A; Liu S; Tan YW; Kwek PZ; Hung AW; Joy J; Hill J; Keller TH; Kang C
Biomol NMR Assign; 2017 Oct; 11(2):225-229. PubMed ID: 28808922
[TBL] [Abstract][Full Text] [Related]
6. In vitro histone lysine methylation by NSD1, NSD2/MMSET/WHSC1 and NSD3/WHSC1L.
Morishita M; Mevius D; di Luccio E
BMC Struct Biol; 2014 Dec; 14():25. PubMed ID: 25494638
[TBL] [Abstract][Full Text] [Related]
7. Structure, Activity and Function of the NSD3 Protein Lysine Methyltransferase.
Rathert P
Life (Basel); 2021 Jul; 11(8):. PubMed ID: 34440470
[TBL] [Abstract][Full Text] [Related]
8. Discovery of a potent and selective proteolysis targeting chimera (PROTAC) degrader of NSD3 histone methyltransferase.
Sun Y; Zhang Y; Chen X; Yu A; Du W; Huang Y; Wu F; Yu L; Li J; Wen C; Yang H; Shi Q; Geng M; Huang X; Xu S
Eur J Med Chem; 2022 Sep; 239():114528. PubMed ID: 35717870
[TBL] [Abstract][Full Text] [Related]
9. Molecular basis of nucleosomal H3K36 methylation by NSD methyltransferases.
Li W; Tian W; Yuan G; Deng P; Sengupta D; Cheng Z; Cao Y; Ren J; Qin Y; Zhou Y; Jia Y; Gozani O; Patel DJ; Wang Z
Nature; 2021 Feb; 590(7846):498-503. PubMed ID: 33361816
[TBL] [Abstract][Full Text] [Related]
10. Discovery of potent small molecule inhibitors of histone lysine methyltransferase NSDs.
Piao L; Gao Y; Xu X; Su Y; Wang YD; Zhou J; Gao Y; Fang J; Li Q; Chang S; Kong R
Eur J Med Chem; 2024 Mar; 268():116264. PubMed ID: 38412693
[TBL] [Abstract][Full Text] [Related]
11. The methyltransferase NSD3 has chromatin-binding motifs, PHD5-C5HCH, that are distinct from other NSD (nuclear receptor SET domain) family members in their histone H3 recognition.
He C; Li F; Zhang J; Wu J; Shi Y
J Biol Chem; 2013 Feb; 288(7):4692-703. PubMed ID: 23269674
[TBL] [Abstract][Full Text] [Related]
12. Fragment-based discovery of a chemical probe for the PWWP1 domain of NSD3.
Böttcher J; Dilworth D; Reiser U; Neumüller RA; Schleicher M; Petronczki M; Zeeb M; Mischerikow N; Allali-Hassani A; Szewczyk MM; Li F; Kennedy S; Vedadi M; Barsyte-Lovejoy D; Brown PJ; Huber KVM; Rogers CM; Wells CI; Fedorov O; Rumpel K; Zoephel A; Mayer M; Wunberg T; Böse D; Zahn S; Arnhof H; Berger H; Reiser C; Hörmann A; Krammer T; Corcokovic M; Sharps B; Winkler S; Häring D; Cockcroft XL; Fuchs JE; Müllauer B; Weiss-Puxbaum A; Gerstberger T; Boehmelt G; Vakoc CR; Arrowsmith CH; Pearson M; McConnell DB
Nat Chem Biol; 2019 Aug; 15(8):822-829. PubMed ID: 31285596
[TBL] [Abstract][Full Text] [Related]
13. Prospect of targeting lysine methyltransferase NSD3 for tumor therapy.
Li D; Tian T; Ko CN; Yang C
Pharmacol Res; 2023 Aug; 194():106839. PubMed ID: 37400043
[TBL] [Abstract][Full Text] [Related]
14. NSD3 in Cancer: Unraveling Methyltransferase-Dependent and Isoform-Specific Functions.
Nuñez Y; Vera S; Baeza V; Gonzalez-Pecchi V
Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38256018
[TBL] [Abstract][Full Text] [Related]
15. [NSD3 suppresses LPS-triggered TNF-α production via promoting the dimethylation of histone H3K36 in macrophages].
Liu Z; Cheng Q; Yang L; Sun Y
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2018 Jun; 34(6):481-487. PubMed ID: 30236198
[TBL] [Abstract][Full Text] [Related]
16. NSD3: Advances in cancer therapeutic potential and inhibitors research.
Xiu S; Chi X; Jia Z; Shi C; Zhang X; Li Q; Gao T; Zhang L; Liu Z
Eur J Med Chem; 2023 Aug; 256():115440. PubMed ID: 37182335
[TBL] [Abstract][Full Text] [Related]
17. Development of a Time-Resolved Fluorescence Resonance Energy Transfer Ultrahigh-Throughput Screening Assay for Targeting the NSD3 and MYC Interaction.
Xiong J; Pecchi VG; Qui M; Ivanov AA; Mo X; Niu Q; Chen X; Fu H; Du Y
Assay Drug Dev Technol; 2018; 16(2):96-106. PubMed ID: 29634317
[TBL] [Abstract][Full Text] [Related]
18. The role of NSD1, NSD2, and NSD3 histone methyltransferases in solid tumors.
Topchu I; Pangeni RP; Bychkov I; Miller SA; Izumchenko E; Yu J; Golemis E; Karanicolas J; Boumber Y
Cell Mol Life Sci; 2022 May; 79(6):285. PubMed ID: 35532818
[TBL] [Abstract][Full Text] [Related]
19. The Brd4 extraterminal domain confers transcription activation independent of pTEFb by recruiting multiple proteins, including NSD3.
Rahman S; Sowa ME; Ottinger M; Smith JA; Shi Y; Harper JW; Howley PM
Mol Cell Biol; 2011 Jul; 31(13):2641-52. PubMed ID: 21555454
[TBL] [Abstract][Full Text] [Related]
20. The Role of Nuclear Receptor-Binding SET Domain Family Histone Lysine Methyltransferases in Cancer.
Bennett RL; Swaroop A; Troche C; Licht JD
Cold Spring Harb Perspect Med; 2017 Jun; 7(6):. PubMed ID: 28193767
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
